Unresectable Gastroesophageal Junction Adenocarcinoma Active Not Recruiting Phase 1 / 2 Trials for Ramucirumab (DB05578)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03008278Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryTreatment